Immuron (NASDAQ:IMRN) achieved record first-half sales for its lead commercial product, Travelan®, reporting a 5% year-over-year increase in global revenue to AUD$4.2 million.
The results, announced Monday, underscore a sustained recovery in the global travel sector and the success of the company’s pivot toward digital-first consumer marketing.
Australia remains the company’s primary revenue driver, contributing AUD$3.3 million to the half-year total—a 13% increase over the same period last year.
The growth came despite a "one-off" reduction in inventory levels following the high-profile merger of major pharmacy distributors Sigma Healthcare and Chemist Warehouse, which temporarily suppressed wholesale orders.
In the United States, sales surged 17% to AUD$0.9 million.
Management attributed the U.S. momentum to an aggressive expansion of social media promotions and new store listings on Amazon and specialized travel health networks.
While Canadian sales faced a steep 85% decline for the half-year due to prior year stocking anomalies, the region showed signs of a sharp turnaround in the second quarter, with sales jumping 191% on a quarter-on-quarter basis.
Beyond its flagship traveler’s diarrhea supplement, Immuron recently diversified its portfolio with the Australian launch of ProIBS®, a medical device for irritable bowel syndrome. The product, which debuted just before the Christmas holiday season, has already secured listings with two of Australia's three largest pharmacy wholesalers and five major retail banner groups.
The company is currently well-capitalized to fund its dual-track strategy of commercial expansion and clinical development.
Immuron is also awaiting key clinical milestones, including Phase 2 trial results for its military-grade diarrhea prevention treatments funded by the U.S. Department of Defense.